EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Concurrent tissue and circulating tumor DNA analysis in renal cell carcinoma: insights from a multimodal database

Chinmay T Jani iD, Elizabeth Tran, Ellen Jaeger, Jianjie Dong, Nabil Husni, Melissa C Stoppler, Adam J Hockenberry, Jacob Mercer, Sumanta Pal, Neeraj Agarwal iD, Toni K Choueiri, Brent Rose und 2 weitere

The Oncologist · 10.04.2026 · 31 (5)

DOI: 10.1093/oncolo/oyag123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 03.04.2026. Verfasst von Chinmay T Jani und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL, 33136, United States. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Circulating Tumor DNA, Kidney Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Circulating tumor DNA (ctDNA) sequencing complements tissue-based next-generation sequencing (NGS), offering noninvasive and serial testing. We explore the mutational landscape of renal cell carcinoma (RCC) using matched tissue and ctDNA data to assess complementarity and clinical significance of molecular alterations.

Methods

From the Tempus multimodal database, we retrospectively analyzed de-identified data from patients with RCC with concurrent tissue (Tempus xT) and ctDNA testing (Tempus xF). Patients with xT and xF matched samples (collected ±90 days of one another) were included. We evaluated socio-demographic and clinical characteristics and selected pathogenic somatic short variants (PSSVs) and copy number variants (CNV). Analyses were restricted to the 104 genes shared by all assays.

Results

Among 392 patients, 66% (n = 259) had metastatic disease. The median time from tissue to blood collection was 21 days. The most common tissue sites were kidney (49%, n = 189) and bone (11%, n = 43). Frequently altered tissue-tested genes were: VHL (59%), PBRM1 (32%), and SETD2 (23%). Most frequently altered genes in ctDNA were TP53 (23%), VHL (18%), BAP1 (6%), and PBRM1 (5%); notably, 176 patients did not have any pathogenic or likely pathogenic variants detected in the 104 genes analyzed. Complementary ctDNA and tissue testing detected 6% more alterations than tissue testing alone, with greater concordance in metastatic cases. Conclusion ctDNA testing offers complementary insights to tissue NGS in RCC, particularly in metastatic disease, suggesting the potential utility of ctDNA in advanced RCC. Longitudinal analysis may enhance delineation of biomarkers of response and resistance at mutation and ctDNA fraction levels.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellCirculating Tumor DNAKidney NeoplasmsBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedHigh-Throughput Nucleotide SequencingRetrospective StudiesMutationAdultDNA Copy Number VariationsTranscription FactorsDNA-Binding ProteinsHistone-Lysine N-Methyltransferase

Stichwörter der Autor:innen

RCCctDNAkidney cancertissue NGS

Substanzen

Circulating Tumor DNABiomarkers, TumorSETD2 protein, humanPBRM1 protein, humanTranscription FactorsDNA-Binding ProteinsHistone-Lysine N-Methyltransferase

Autor:innen und Institutionen

  • University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL, 33136, United States.
  • University of California San Diego, La Jolla, CA, 92037, United States.
  • Tempus AI, Inc., Chicago, IL, 60654, United States.
  • Scripps Institute, San Diego, La Jolla, CA, 92037, United States.
  • City of Hope, Duarte, CA, 91010, United States.
  • Huntsman Cancer Center, Salt Lake City, UT, 84112, United States.

ORCID-Profile: Chinmay T Jani, Neeraj Agarwal

Zitieren

APA

Jani, C. T., Tran, E., Jaeger, E., Dong, J., Husni, N., Stoppler, M. C., Hockenberry, A. J., Mercer, J., Pal, S., Agarwal, N., Choueiri, T. K., Rose, B., Bagrodia, A., & McKay, R. R. (2026). Concurrent tissue and circulating tumor DNA analysis in renal cell carcinoma: insights from a multimodal database. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag123

Vancouver

Jani CT, Tran E, Jaeger E, Dong J, Husni N, Stoppler MC, et al. Concurrent tissue and circulating tumor DNA analysis in renal cell carcinoma: insights from a multimodal database. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag123

BibTeX
@article{Jani2026,
  author = {Jani, Chinmay T and Tran, Elizabeth and Jaeger, Ellen and Dong, Jianjie and Husni, Nabil and Stoppler, Melissa C and Hockenberry, Adam J and Mercer, Jacob and Pal, Sumanta and Agarwal, Neeraj and Choueiri, Toni K and Rose, Brent and Bagrodia, Aditya and McKay, Rana R},
  title = {Concurrent tissue and circulating tumor DNA analysis in renal cell carcinoma: insights from a multimodal database},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {5},
  doi = {10.1093/oncolo/oyag123}
}
Kostenlos starten →